ImmunityBio, Inc. (IBRX)
7.91
+0.19
(+2.46%)
USD |
NASDAQ |
Sep 11, 16:00
7.92
+0.01
(+0.13%)
After-Hours: 20:00
ImmunityBio Enterprise Value : 9.203B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 9.203B |
| September 10, 2026 | 9.003B |
| September 09, 2026 | 9.361B |
| September 08, 2026 | 9.603B |
| September 04, 2026 | 9.382B |
| September 03, 2026 | 9.498B |
| September 02, 2026 | 9.245B |
| September 01, 2026 | 9.161B |
| August 31, 2026 | 9.245B |
| August 28, 2026 | 9.350B |
| August 27, 2026 | 9.719B |
| August 26, 2026 | 9.561B |
| August 25, 2026 | 9.498B |
| August 24, 2026 | 8.855B |
| August 21, 2026 | 9.076B |
| August 20, 2026 | 9.129B |
| August 19, 2026 | 9.435B |
| August 18, 2026 | 9.003B |
| August 17, 2026 | 9.213B |
| August 14, 2026 | 8.845B |
| August 13, 2026 | 8.929B |
| August 12, 2026 | 9.024B |
| August 11, 2026 | 8.876B |
| August 10, 2026 | 8.761B |
| August 07, 2026 | 8.919B |
| Date | Value |
|---|---|
| August 06, 2026 | 8.581B |
| August 05, 2026 | 8.508B |
| August 04, 2026 | 8.192B |
| August 03, 2026 | 8.402B |
| July 31, 2026 | 8.423B |
| July 30, 2026 | 8.718B |
| July 29, 2026 | 8.065B |
| July 28, 2026 | 8.213B |
| July 27, 2026 | 8.234B |
| July 24, 2026 | 8.350B |
| July 23, 2026 | 8.666B |
| July 22, 2026 | 8.782B |
| July 21, 2026 | 9.371B |
| July 20, 2026 | 8.766B |
| July 17, 2026 | 8.961B |
| July 16, 2026 | 8.718B |
| July 15, 2026 | 9.013B |
| July 14, 2026 | 9.171B |
| July 13, 2026 | 9.076B |
| July 10, 2026 | 9.529B |
| July 09, 2026 | 10.21B |
| July 08, 2026 | 10.14B |
| July 07, 2026 | 10.10B |
| July 06, 2026 | 10.26B |
| July 02, 2026 | 10.81B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 53.59B |
| Sarepta Therapeutics, Inc. | 2.417B |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -230.39M |
| Revenue (Quarterly) | 51.24M |
| Total Expenses (Quarterly) | 281.62M |
| EPS Diluted (Quarterly) | -0.2194 |
| Gross Profit Margin (Quarterly) | 90.82% |
| Profit Margin (Quarterly) | -449.6% |
| Earnings Yield | -12.25% |
| Normalized Earnings Yield | -6.882 |